Ogise, JosiahMumo, RuthNyachieo, AtungaMutiso, JoshuaKamau, JosephOnkoba, Nyamongo2016-12-082016-12-082016-04Pathogen & Infectious Disease 2016; 2: e1259. doi: 10.14800/pid.1259; http://www.smartscitech.com/index.php/pidhttp://ir-library.ku.ac.ke/handle/123456789/15232doi:10.14800/pid.1259Malaria leads in global rates of mortality and morbidity majorly borne by children aged below five years and primigravida women in developing countries. According to WHO, the cases of malaria infections in 2014 declined, despite cases of parasite resistance to available anti-malarial drugs and anopheline mosquitoes resistant to insecticides being reported. Therefore, there is need for an improved malaria control strategy including an effective malaria vaccine which can confer blood stage immunity and prevent development of clinical malaria. This venture has been explored for several decades resulting in discovery of promising antigen candidates but we lack appropriate adjuvants for human use capable of boosting immunogenicity of this antigens. In this review, we highlight limitations of various antigens in conjunction with adjuvants used and provide insight on new strategies of improving vaccine immunogenicity by incorporating immunomodulatory molecules and epitopes. Keywords: Malaria; adjuvants; immunogenicity; protection; vaccines; clinical trialsenMalariaAdjuvantsImmunogenicityProtectionVaccinesClinical trialsArticle